Generative AI for life sciences

Just as companies must design clinical trials to ensure accuracy, legitimacy, and efficacy, they must also carefully manage the deployment of generative AI throughout the enterprise. At Capgemini, we believe this technology will evolve rapidly over the next few years and have identified three phases of this evolution – exploration, augmentation, and re-invention. Now is the time for organizations to plan their generative AI strategy and explore carefully selected use cases in a controlled environment.